Purple Biotech Updates on Clinical Pipeline, Targets H1 2027 for Lead Program's First-in-Human Trial
PPBT sits 17% above its 52-week low of $1.42 on light trading volume (0.1× avg).
Summary
Purple Biotech released an updated corporate presentation detailing its clinical pipeline, including a H1 2027 target for first-in-human trials for its lead program IM1240 and positive Phase 2 data for CM24 in pancreatic cancer.
Key Events · Product Development and Regulatory · PPBT
-
Lead Program IM1240 Clinical Timeline
First-in-human (FIH) clinical trials for the lead CAPTN-3 tri-specific antibody, IM1240, are targeted for H1 2027, following IND submission in 2027. Phase 1 results are expected in H1 2028.
-
CM24 Phase 2 Proof-of-Concept
Positive Phase 2 data for CM24 in metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrated a 19% reduction in risk of death and 25% reduction in risk of progression or death, with significant improvements in biomarker-enriched patients.
-
NT219 Phase 2 Advancement
The small molecule degrader NT219 is advancing in a Phase 2 study initiated in June 2025 for recurrent/metastatic Head & Neck Cancer.
-
Cash Runway Update
The company reported a cash position of $6.4 million as of March 31, 2026, providing a runway into H1 2027. This cash position was previously reported on 2026-05-15.
Analysis · PPBT · Life Sciences
This filing provides a comprehensive update on Purple Biotech's clinical pipeline, highlighting key milestones and positive data. The lead program, IM1240, is on track for IND submission in 2027 and first-in-human trials in H1 2027. Additionally, the company reported positive Phase 2 proof-of-concept data for CM24 in pancreatic ductal adenocarcinoma, particularly in biomarker-enriched patients, demonstrating significant improvements in overall survival and progression-free survival. These updates offer a clear development roadmap and clinical validation for multiple assets.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPBT was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $1.42 to $29.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.